|
Fortune: Cheapskates in a pricey stock market. value investing 1988 Investorss
Content: HighBeam Research, Free Preview: 'Cheapskates in a pricey stock market. value investing 1988 Investorss '... Full Membership required for unlimited access. Free 7-day trial. Comprehensive archive of newspapers, magazines, trade journals, TV and radio ...
Marketocracy
Content: Marketocracy family of mutual funds, including Free Performance Tracker reports
Thaistocks.com :: Independent Unbiased Objective. Founded 04/30/1997. A knowledge
Content: Independent Unbiased Objective. Founded 04/30/1997. A knowledge bank on expertise
Buy The Dividend Connection: How Dividends Create Value in the Stock Market -
Content: The Dividend Connection: How Dividends Create Value in the Stock Market - Price new $24.95, used price $24.50. Search Amazon.com for more books by Geraldine Weiss plus many more Investment analysis books. For a limited time, get free shipping on orders ove
Street Smart Investing: A Price-Value Approach to Stock Market Profits Paperback
Content: Street Smart Investing: A Price-Value Approach to Stock Market Profits in Paperback, ISBN 0394724240, (condition - Acceptable). Search for other books by ARRAY(0x866b43c). We have millions of new & used books at bargain prices.
Yahoo! Finance
Content: Kentucky farmer Paul Hornback strips tobacco leaves from their stocks, forming bales bound for America's cigarette factories. It is timeless autumn toil in a land where the golden dried leaves were once a currency of their own
Warren Buffett meets Sherlock Holmes: Stock Market Software
Content: Stock market software and information based on the methods of Warren Buffett to
help YOU find great companies that make money year after year.
Neural Network Stock Market Value
Content: Higher returns with lower risk with Neural network
valuation of common stocks.
UBC Election Stock Market - Value Chart
BigCharts - Charting a World of Investment Information
Content: NEW YORK (CBS.MW) -- Pfizer said Sunday said it has reached an agreement to buy Michigan-based drug developer Esperion Therapeutics for about $1.3 billion cash to gain access to its promising cholesterol treatment
|